Analysis of prognostic factors in 135 patients with pulmonary metastasis from esophageal squamous cell carcinoma
Cui Xiaoying1, Miao Xianyuan2,3, Sheng Liming2,3, Cheng Lei2,3, Chen Ying2,3, Du Xianghui2,3
1Department of Oncology, Affiliated Hospital of Jiaxing University, Jiaxing 314000, China; 2Department of Thoracic Radiotherapy,The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, China; 3Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China
Abstract：Objective To investigate the prognostic factors of patients with esophageal squamous cell carcinoma with pulmonary metastasis. Methods Clinical characteristics of 135 esophageal squamous cell carcinoma patients presenting with pulmonary metastasis after treatment in Zhejiang Cancer Hospital from 2008 to 2018 were retrospectively analyzed. Thesurvival rate was calculated by Kaplan-Meier method. Univariate analysis was performed by log-rank test. Multivariate prognostic analysis was conducted by Cox models. Results The median follow-up time of 135 patients with esophageal squamous cell carcinoma was 94.2 months (19.5-258.9 months), and 109 patients died (80.7%). The 1-and 2-year overall survival rates were 47.4% and 25.1%, with the median survival time was 11.1 months (7.3-14.9 months).Univariate prognostic analysis showed that age, number of lung metastases, treatment of lung metastases, lymph node metastasis, distant organ metastasis, and the interval between the first treatment and lung metastasis were the prognostic factors of esophageal squamous cell carcinoma with lung metastasis (all P<0.05). Multivariate analysis demonstrated that age and number of lung metastases were the independent prognostic factors for patients with esophageal squamous cell carcinoma with lung metastases (all P<0.05). Conclusions Age and number of lung metastases are the independent prognostic factors for patients with esophageal squamous cell carcinoma with lung metastases. Surgery or radiotherapy-based regional therapy can enhance clinical prognosis.
Cui Xiaoying,Miao Xianyuan,Sheng Liming et al. Analysis of prognostic factors in 135 patients with pulmonary metastasis from esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(2): 149-152.
[1] Wu SG, Zhang WW, He ZY, et al. Sites of metastasis and overall survival in esophageal cancer:a population-based study[J]. Cancer Manag Res, 2017, 9:781-788. DOI:10.2147/CMAR. S150350. [2] Kanamori J, Aokage K, Hishida T, et al. The role of pulmonary resection in tumors metastatic from esophageal carcinoma[J]. Jpn J Clin Oncol, 2017, 47(1):25-31. DOI:10.1093/jjco/hyw141. [3] Takemura M, Sakurai K, TakII M, et al. Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer:prognosis and outcome[J]. J Cardiothorac Surg, 2012, 7:103. DOI:10.1186/1749-8090-7-103. [4] Hamai Y, Hihara J, Emi M, et al. Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma[J]. World J Surg, 2018, 42(7):2190-2198. DOI:10.1007/s00268-017-4430-8. [5] Muro K, Hamaguchi T, Ohtsu A, et al. A phase Ⅱ study of single-agent docetaxel in patients with metastatic esophageal cancer[J]. Ann Oncol, 2004, 15(6):955-959. DOI:10.1093/annonc/mdh231. [6] Ichida H, Imamura H, Yoshimoto J, et al. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma[J]. World J Surg, 2013, 37(2):398-407. DOI:10.1007/s00268-012-1830-7. [7] Kobayashi N, Kohno T, Haruta S, et al. Pulmonary metastasectomy secondary to esophageal carcinoma:long-term survival and prognostic factors[J]. Ann Surg Oncol, 2014, 21(Suppl 3):S365-369. DOI:10.1245/s10434-014-3677-7. [8] Shiono S, Kawamura M, Sato T, et al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases[J]. J Thorac Oncol, 2008, 3(9):1046-1049. DOI:10.1097/JTO.0b013e318183aa0c. [9] Hirose K, Saeki H, Nakashima Y, et al. Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma:a case report[J]. Surg Case Rep, 2019, 5(1):72. DOI:10.1186/s40792-019-0634-5. [10] Ghaly G, Harrison S, Kamel MK, et al. Predictors of survival after treatment of oligometastases after esophagectomy[J]. Ann Thorac Surg, 2018, 105(2):357-362. DOI:10.1016/j.athoracsur.2017.10.039. [11] 李慧,陈健,罗会芹,等. 初诊肝和(或)肺转移食管鳞癌患者的预后因素分析[J]. 肿瘤,2016, 36(2):187-193. DOI:10.3781/j.issn.1000-7431.2016.33.696. Li H, Chen J, Luo HQ, et al. Analysis of prognostic factors in patients with first diagnosed liver and (or) lung metastatic esophageal squamous carcinoma[J]. Tumor, 2016, 36(2):187-193. DOI:10.3781/j.issn.1000-7431.2016.33.696.
2022, Vol. 31 
